Celladon is a privately held biotechnology company founded with the goal of becoming the leader in developing molecular therapies for the treatment of heart failure. Our products target the key enzyme deficiency in advanced heart failure, SERCA2a, which regulates calcium cycling and contractility in heart muscle cells. Our initial product candidate, MYDICAR®, delivers the gene for the SERCA2a enzyme. The Phase 2 CUPID clinical trial shows sustained improvement at one year in cardiac function parameters and quality of life. A 200 patient Phase 2b study of MYDICAR was initiated in August, 2012. Celladon also conducts pre-clinical research on our proprietary platform of small molecule activators of SERCA enzymes for the treatment of metabolic and cardiovascular diseases.
Heart failure costs the nation $34.4 billion1 each year. More than 670,000 new cases of heart failure were diagnosed in 2010 and that number increases yearly. Without a breakthrough in treatment, 70 percent of patients will die within 10 years and 50 percent will die within five years. Celladon’s products could dramatically lower the cost of care, improve the prognosis for heart failure and provide a better quality of life for patients in the terminal stages of the disease.
Our management team, board of directors and scientific advisors is comprised of industry recognized professionals who possess broad scientific knowledge in cardiovascular disease and extensive experience building biotechnology companies and managing drug development through clinical trials to FDA approval.
Celladon Corporation is based in San Diego, California. Current investors include Enterprise Partners Venture Capital, Venrock Associates, Johnson & Johnson Development Corporation, Pfizer Venture Investments, Lundbeckfond Ventures, Novartis Venture Funds, GBS Ventures Partners, Hambrecht & Quist Capital Management, LSP Life Sciences Partners, and MPM Capital.
1 Heidenriech PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933–44.
...The mean duration of hospitalization in the MYDICAR® high dose group during the 12-month period was 0.4 days per patient compared with 4.5 days per patient in the placebo group. This finding is especially noteworthy because heart failure is the leading cause of hospitalization in Americans 65 years of age and older...